{"title":"评价直接口服抗凝剂与华法林在重度肥胖非瓣膜性心房颤动患者中的疗效和安全性：一项回顾性队列研究。","authors":"Shady Ezaldin, Mahmoud Abdelsalam, Frank Annie, Julton Tomanguillo Chumbe, Elie Gharib","doi":"10.1016/j.heliyon.2024.e41596","DOIUrl":null,"url":null,"abstract":"<p><p>•DOACs are effective and safe in very morbidly obese AF patients (BMI ≥50 kg/m<sup>2</sup>).•DOACs show similar stroke and bleeding risks as warfarin in this population.•Findings support DOACs in anticoagulation guidelines for very morbidly obese patients.</p>","PeriodicalId":12894,"journal":{"name":"Heliyon","volume":"11 1","pages":"e41596"},"PeriodicalIF":3.6000,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11758958/pdf/","citationCount":"0","resultStr":"{\"title\":\"\\\"Evaluating the efficacy and safety of direct oral anticoagulants compared to warfarin in very morbidly obese patients with non-valvular atrial fibrillation: A retrospective cohort study\\\".\",\"authors\":\"Shady Ezaldin, Mahmoud Abdelsalam, Frank Annie, Julton Tomanguillo Chumbe, Elie Gharib\",\"doi\":\"10.1016/j.heliyon.2024.e41596\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>•DOACs are effective and safe in very morbidly obese AF patients (BMI ≥50 kg/m<sup>2</sup>).•DOACs show similar stroke and bleeding risks as warfarin in this population.•Findings support DOACs in anticoagulation guidelines for very morbidly obese patients.</p>\",\"PeriodicalId\":12894,\"journal\":{\"name\":\"Heliyon\",\"volume\":\"11 1\",\"pages\":\"e41596\"},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2025-01-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11758958/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Heliyon\",\"FirstCategoryId\":\"103\",\"ListUrlMain\":\"https://doi.org/10.1016/j.heliyon.2024.e41596\",\"RegionNum\":3,\"RegionCategory\":\"综合性期刊\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/15 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"MULTIDISCIPLINARY SCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Heliyon","FirstCategoryId":"103","ListUrlMain":"https://doi.org/10.1016/j.heliyon.2024.e41596","RegionNum":3,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/15 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MULTIDISCIPLINARY SCIENCES","Score":null,"Total":0}
"Evaluating the efficacy and safety of direct oral anticoagulants compared to warfarin in very morbidly obese patients with non-valvular atrial fibrillation: A retrospective cohort study".
•DOACs are effective and safe in very morbidly obese AF patients (BMI ≥50 kg/m2).•DOACs show similar stroke and bleeding risks as warfarin in this population.•Findings support DOACs in anticoagulation guidelines for very morbidly obese patients.
期刊介绍：
Heliyon is an all-science, open access journal that is part of the Cell Press family. Any paper reporting scientifically accurate and valuable research, which adheres to accepted ethical and scientific publishing standards, will be considered for publication. Our growing team of dedicated section editors, along with our in-house team, handle your paper and manage the publication process end-to-end, giving your research the editorial support it deserves.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
